{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:13:07Z","timestamp":1772914387226,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.dmpk.2015.04.001","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T04:31:33Z","timestamp":1428726693000},"page":"257-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Serum flecainide S\/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity"],"prefix":"10.1016","volume":"30","author":[{"given":"Kosuke","family":"Doki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Aonuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2015.04.001_bib1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2015.04.001_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0002-9149(87)91178-7","article-title":"Flecainide acetate for conversion of acute supraventricular tachycardia to sinus rhythm","volume":"59","author":"Crozier","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0025-6196(12)65077-0","article-title":"New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone","volume":"62","author":"Kreeger","year":"1987","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.dmpk.2015.04.001_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1211\/0022357055128","article-title":"Assessment of serum flecainide trough levels in patients with tachyarrhythmia","volume":"57","author":"Homma","year":"2005","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/FPC.0b013e328361fb8d","article-title":"SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients","volume":"23","author":"Doki","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.dmpk.2015.04.001_bib6","doi-asserted-by":"crossref","first-page":"41B","DOI":"10.1016\/0002-9149(84)90501-0","article-title":"Metabolism of flecainide","volume":"53","author":"Conard","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-9556(25)07741-4","article-title":"Biotransformation and elimination of 14C-flecainide acetate in humans","volume":"12","author":"McQuinn","year":"1984","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2015.04.001_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2125.2009.03435.x","article-title":"Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism","volume":"68","author":"Doki","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/clpt.1989.73","article-title":"The influence of the sparteine\/debrisoquin phenotype on the disposition of flecainide","volume":"45","author":"Mikus","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2015.04.001_bib10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00228-006-0188-x","article-title":"Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia","volume":"62","author":"Doki","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2125.1989.tb03542.x","article-title":"Stereoselective disposition of flecainide in relation to the sparteine\/debrisoquine metaboliser phenotype","volume":"28","author":"Gross","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00280070","article-title":"Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH","volume":"40","author":"Gross","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2125.1992.tb04035.x","article-title":"Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias","volume":"33","author":"Birgersdotter","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/bmc.3143","article-title":"Stereoselective analysis of flecainide enantiomers using reversed-phase liquid chromatography for assessing CYP2D6 activity","volume":"28","author":"Doki","year":"2014","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.dmpk.2015.04.001_bib15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jpba.2004.04.009","article-title":"Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography","volume":"35","author":"Doki","year":"2004","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.dmpk.2015.04.001_bib16","first-page":"121","article-title":"CYP2D6-dependent bufuralol 1\u2032-hydroxylation assayed by reverse-phase ion-pair high-performance liquid chromatography with fluorescence detection","volume":"320","author":"Crespi","year":"2006","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.dmpk.2015.04.001_bib18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ab.2004.11.038","article-title":"High-throughput detection of multiple genetic polymorphisms influencing drug metabolism with mismatch primers in allele-specific polymerase chain reaction","volume":"337","author":"Ishiguro","year":"2005","journal-title":"Anal Biochem"},{"key":"10.1016\/j.dmpk.2015.04.001_bib19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/FPC.0b013e3283588fe5","article-title":"CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis","volume":"22","author":"Doki","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.dmpk.2015.04.001_bib20","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clpt.2004.08.020","article-title":"Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension","volume":"76","author":"Zineh","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2015.04.001_bib21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2710.2012.01333.x","article-title":"Serum dextromethorphan\/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice","volume":"37","author":"Jurica","year":"2012","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.dmpk.2015.04.001_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00280107","article-title":"Flecainide: evidence of non-linear kinetics","volume":"41","author":"Boriani","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s002280100299","article-title":"Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients","volume":"57","author":"Lohmann","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.04.001_bib24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-2003-43049","article-title":"A\u00a0CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients","volume":"36","author":"Ieiri","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.dmpk.2015.04.001_bib25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/pr.58.3.6","article-title":"Pharmacogenetics, drug-metabolizing enzymes, and clinical practice","volume":"58","author":"Gardiner","year":"2006","journal-title":"Pharmacol Rev"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436715000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436715000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:52:29Z","timestamp":1761162749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1347436715000233"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2015.04.001","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum flecainide S\/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2015.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}